1 / 12

VBWG

VBWG. Results from ASCOT-BPLA: A nglo- S candinavian C ardiac O utcomes T rial– B lood P ressure L owering A rm. VBWG. Rationale. Cardiovascular (CV) disease continues to be the chief cause of mortality and morbidity worldwide Most of this is due to coronary heart disease (CHD)

hija
Download Presentation

VBWG

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VBWG Results from ASCOT-BPLA:Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm

  2. VBWG Rationale • Cardiovascular (CV) disease continues to be the chief cause of mortality and morbidity worldwide • Most of this is due to coronary heart disease (CHD) • Multiple risk factors have synergistic effects in the pathogenesis of CV disease • Combination treatment regimens using 2 agents are recommended to reach target BP goals • Limited outcome data have led to an investigation comparing standard vs newer antihypertensive treatment options

  3. VBWG ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial ASCOT — multicenter, international trial comparing treatment regimens Study 1: ASCOT-LLA • Double-blind, randomized, placebo-controlled trial of a lipid-lowering agent in a sample of the total ASCOT patient population Study 2: ASCOT-BPLA • Prospective, randomized, open, blinded endpoint (PROBE) design comparing two antihypertensive regimens in the total ASCOT patient population These slides present results from the newly released ASCOT-BPLA arm Sever PS et al. Lancet. 2003;361:1149-58. Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  4. VBWG ASCOT-BPLA: Study design Design: Double-blind, placebo controlled, randomized Population: N = 19,257 with hypertension and ≥3 other CV risk factors Treatment: Amlodipine 5–10 mg ± perindopril 4–8 mg prn(n = 9639) Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg/potassium prn (n = 9618) Primary outcome: Nonfatal MI (including silent MI) and fatal CHD Secondary outcome: All-cause mortality, stroke, nonfatal MI (excluding silent MI), all coronary events, CV events/procedures, CV mortality, fatal/nonfatal HF

  5. VBWG ASCOT-BPLA: Trial profile 19,342 Randomized 85 Excluded because of BP measurement irregularities 19,257 Evaluable 9639 Assigned amlodipine- based regimen 9618 Assigned atenolol- based regimen 171 Incomplete information 102 Alive at last visit 36 Withdrew consent 33 Lost to follow-up 121 Incomplete information 81 Alive at last visit 24 Withdrew consent 16 Lost to follow-up 9639 Assessed for primary outcome intention-to-treat basis 9518 Complete information (8780 alive, 738 dead) 9618 Assessed for primary outcome intention-to-treat basis 9447 Complete information (8627 alive, 820 dead) Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  6. VBWG ASCOT-BPLA: Treatment algorithm for BP targets Amlo 10 mg +peri 8 mg(2 x 4 mg) +doxa 8 mg BP medication titrated to achieve target: No diabetes: <140/90 mm Hg Diabetes: <130/80 mm Hg Amlo 10 mg +peri 8 mg(2 x 4 mg) +doxa 4 mg Amlo 10 mg +peri 8 mg(2 x 4 mg) Amlo 10 mg +peri 4 mg Amlo10 mg Amlo 5 mg In each arm, pts with total cholesterol ≤6.5 mmol/L randomized to atorvastatin (10 mg) or placebo daily(n = 10,297) 19,342 patients 40–79 ywithU N T R E A T E D SBP ≥160 mmHg and/orDBP ≥100 mmHg ORT R E A T E D SBP ≥140 mmHg and/or DBP ≥90 mmHg Atenolol100 mg +BFZ 2.5 mg + K+ + doxa 8 mg Atenolol100 mg +BFZ 2.5 mg + K+ + doxa 4 mg Atenolol100 mg +BFZ 2.5 mg + K+ Atenolol100 mg +BFZ 1.25 mg + K+ RANDOMIZATION Atenolol100 mg Atenolol50 mg 5 Years or 1150 primary events Amlo = amlodipine; Peri = perindopril; Doxa = doxazosin GITS (Gastrointestinal Transport System); BFZ = bendroflumethiazide Sever PS et al. J Hypertens. 2001;19:1139-47.

  7. VBWG ASCOT-BPLA: Reduction in primary outcome (nonfatal MI and fatal CHD) 10 8 HR = 0.90 (95% CI, 0.79–1.02) RRR = 10% P = 0.1052 6 Proportionof events (%) 4 Atenolol-based regimen* 2 Amlodipine-based regimen† 0 0 1 2 3 4 5 6 Time since randomization (years) Number at risk Amlodipine-based regimen 9639 9475 9337 9168 8966 7863 (429 events) Atenolol-based regimen 9618 9470 9290 9083 8858 7743 (474 events) *Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg/potassium prn†Amlodipine 5–10 mg ± perindopril 4–8 mg prn Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  8. VBWG ASCOT-BPLA: Reduction in fatal and nonfatal stroke 10 8 HR = 0.77 (95% CI, 0.66–0.89) RRR = 23% P = 0.0003 6 Proportionof events (%) 4 Atenolol-based regimen* 2 Amlodipine-based regimen† 0 6 0 1 2 3 4 5 Time (years) Number at risk Amlodipine-based regimen 9639 9483 9331 9156 8972 7863 (327 events) Atenolol-based regimen 9618 9461 9274 9059 8843 7720 (422 events) *Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg/potassium prn†Amlodipine 5–10 mg ± perindopril 4–8 mg prn Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  9. VBWG ASCOT-BPLA: Additional reductions in group receiving the amlodipine-based regimen Amlodipine-based*(n = 9639) Atenolol-based † (n = 9618) Rate/1000patient years Rate/1000patient years <0.05 <0.01 <0.0001 <0.05 0.001 <0.001 NS <0.0001 <0.05 Secondary endpoints Nonfatal MI (excluding silent) 7.4 8.5 + fatal CHD Total coronary endpoint 14.6 16.8 Total CV events and procedures 27.4 32.8 All-cause mortality 13.9 15.5 CV mortality 4.9 6.5 Fatal/nonfatal stroke 6.2 8.1 Fatal/nonfatal HF 2.5 3.0 Tertiary endpoints Development of diabetes 11.0 15.9 Development of renal impairment 7.7 9.1 Amlodipine-based better Atenolol-based better P 0.50 0.70 1.00 1.45 2.00 *Amlodipine 5–10 mg ± perindopril 4–8 mg prn †Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg/potassium prn Unadjusted risk reduction Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  10. Atenolol-based regimen* Amlodipine-based regimen† VBWG ASCOT-BPLA: Reductions in BP over time 180 Systolic BP 160 BP 137.7 136.1 140 Mean difference = 2.7, P < 0.0001 Blood pressure(mm Hg) 120 Diastolic BP 100 79.2 77.4 80 Mean difference = 1.9, P < 0.0001 60 0 Final visit (mean 5.7 [SD 0.6], range 4.6–7.3) 4.0 0.5 1.5 2.0 3.5 4.5 2.5 0 1.0 3.0 5.0 5.5 Time (years) *Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg/potassium prn†Amlodipine 5–10 mg ± perindopril 4–8 mg prn Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  11. VBWG ASCOT-BPLA: Overall results • Study stopped prematurely after 5.5-year median follow-up because of higher death rate in assigned atenolol-based-regimen group • Group receiving amlodipine-based regimen had nonsignificant 10% reduction in primary outcome (nonfatal MI plus fatal CHD) and significant reductions in nearly all secondary CV endpoints and new-onset diabetes Dahlöf B et al; ASCOT Investigators. Lancet. 2005;366:895-906.

  12. VBWG ASCOT-BPLA: Summary • Newer antihypertensive drug regimens should be considered in preference to older beta-blocker ± diuretic therapies • Amlodipine-based regimen was beneficial in lowering BP and prevention of CV events compared to beta-blocker ± diuretic-based regimen • Amlodipine ± perindopril showed reductions in: • Major CV events 16% • New-onset diabetes 30% • Stroke 23% • Mortality 11% • Improved BP control* with amlodipine ± perindopril may explain some, but not all, of the benefit ASCOT results support the use of newer drugs, in multi-drug combinations, to modify risk factors and/or metabolic disturbances, especially in patients with complicated hypertension Dahlöf B et al. Lancet. 2005;366:895-906. Poulter NR et al. Lancet. 2005;366:907-13. *mean in-trial systolic BP difference 2.7 mm Hg

More Related